PTOV1 and laryngeal carcinoma: Targeting autophagy (hydroxychloroquine) in patient-derived cell lines that were cisplatin resistant (high PTOV1) resulted in vast cell killing, indicating the autophagy dependence and suggests that PTOV1 could be used as biomarker for selection of laryngeal cancer patients that would likely benefit from concurrent autophagy targeting.